Berlin - Delayed Quote EUR

Rocket Pharmaceuticals Inc (9IP1.BE)

20.60

-0.01

(-0.05%)

At close: April 26 at 8:30 PM GMT+2

Should You Retain Your Conviction in Rocket Pharmaceuticals (RCKT)?

Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. The fund advanced 8.92% (Institutional Shares) in the quarter compared to an 8.52% gain for the Russell 3000 Health Care Index (benchmark) and a 10.56% increase for the S&P […]

Insider Monkey 3 days ago

RCKTW
EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia

The EMA accepts Rocket's (RCKT) regulatory submission seeking approval for RP-L102, a gene therapy for a rare genetic disorder called fanconi anemia that affects the bone marrow.

Zacks 24 days ago

RCKTW

ANIP

LGNZZ
Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia

CRANBURY, N.J., April 02, 2024--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the European Medicines Agency (EMA) accepted the Marketing Authorization Application (MAA) for RP-L102, its lentiviral (LV) vector-based investigational gene therapy for Fanconi Anemia (FA), complementation group A, a rare genetic disorder caused by muta

Business Wire 25 days ago

RCKT

RCKTW
Why Is Rocket Pharmaceuticals (RCKT) Down 13.6% Since Last Earnings Report?

Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks last month

RCKTW

MRNA
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team

CRANBURY, N.J., March 26, 2024--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the appointment of Aaron Ondrey, as Chief Financial Officer, and the further evolution of its corporate leadership team through key appointments with existing team members. These leadership announcements build on and expand Rocket’s preparedness for its plann

Business Wire last month

RCKT

RCKTW
Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4

Rocket Pharmaceuticals' (RCKT) fourth-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.

Zacks last month

RCKTW

PBYI

ADMA
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

CRANBURY, N.J., February 26, 2024--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and operational results for the fourth quarter and year ended December 31, 2023.

Business Wire last month

RCKT

RCKTW
15 Best Strong Buy Stocks To Invest In

In this piece, we will take a look at the 15 best strong buy stocks to invest in. If you want to skip our overview of analyst ratings and the finance industry, then you can take a look at the 5 Best Strong Buy Stocks To Invest In. The financial services industry is one of […]

Insider Monkey 2 months ago

BIDU

UBER

LI
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

CRANBURY, N.J., February 13, 2024--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the U.S. Food and Drug Administration (FDA) has extended the Priority Review period for the Biologics License Application (BLA) for KRESLADI™ (marnetegragene autotemcel) for severe Leukocyte Adhesion Deficiency-I (LAD-I). The FDA extended the review period

Business Wire 2 months ago

RCKT

RCKTW
7 Speculative Stocks to Double Your Money THIS Year

While investors should probably direct the majority of their market-earmarked funds toward slow-and-steady ideas – à la Warren Buffett – sometimes, we end up with gambling money. And in that case, speculative stocks to double your money might make sense. To be 100% clear, anytime investors venture into high-risk, high-reward stocks, there’s a reason for the warning. Mainly, when market participants buy established blue chips, they’re paying a premium for the predictability. It’s like paying for

InvestorPlace 3 months ago

CRNT

DYN

CAN
Should You Maintain Your Conviction in Rocket Pharmaceuticals (RCKT)?

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. The fund advanced 7.69% (Institutional Shares) in the quarter compared to a 6.96% gain for the Russell 3000 Health Care Index and an 11.69% increase for the S&P 500 Index. […]

Insider Monkey 3 months ago

RCKTW

^GSPC
Rocket Pharmaceuticals, Inc.'s (NASDAQ:RCKT) Shift From Loss To Profit

With the business potentially at an important milestone, we thought we'd take a closer look at Rocket Pharmaceuticals...

Simply Wall St. 3 months ago

RCKTW
Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference

CRANBURY, N.J., January 02, 2024--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that Gaurav Shah, M.D., Chief Executive Officer, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 3:45 p.m. PT.

Business Wire 3 months ago

RCKT

RCKTW
11 Most Promising Biotech Stocks to Buy According to Analysts

In this article, we will take a look at the 11 most promising biotech stocks to buy according to analysts. To skip our analysis of the recent trends, and market activity, you can go directly to see the 5 Most Promising Biotech Stocks to Buy According to Analysts. The biotech industry is making a resurgence […]

Insider Monkey 4 months ago

RCKTW

MRNA

CYTK
Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors

CRANBURY, N.J., December 12, 2023--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the appointment of R. Keith Woods as an independent, non-executive director to its Board of Directors. Mr. Woods is a seasoned executive with more than 30 years of experience spanning commercialization, global operations, business strategy and supply

Business Wire 4 months ago

RCKT

RCKTW
Billionaire Lee Ainslie’s Top 10 Stock Picks

In this article, we will take a look at Billionaire Lee Ainslie’s top 10 stock picks. For more Ainslie’s stocks, head on over to Billionaire Lee Ainslie’s Top 5 Stock Picks. Hedge fund managers are known for investing in various asset classes in the race to unlock value in the market. But not Lee Ainslie, a […]

Insider Monkey 5 months ago

MSFT

V

NU
Rocket (RCKT) Surges 40% in 3 Months on Regulatory Updates

Rocket (RCKT) gains 40% in three months on positive regulatory updates on its key candidates.

Zacks 5 months ago

RCKT

DVAX

LGNZZ
Wall Street Analysts See a 167.09% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High?

The consensus price target hints at a 167.1% upside potential for Rocket Pharmaceuticals (RCKT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks 5 months ago

RCKT
Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress

CRANBURY, N.J., November 06, 2023--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial results for the quarter ending September 30, 2023, and updates from the Company’s key pipeline developments, business operations and upcoming milestones.

Business Wire 5 months ago

RCKT
Rocket Pharmaceuticals Stock Sees Improved Price Strength

Rocket Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investor's Business Daily 5 months ago

RCKT

Performance Overview

Return	9IP1.BE	S&P 500
YTD	-26.11%	+6.92%
1-Year	+27.79%	+25.26%
3-Year	-45.21%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Rocket Pharmaceuticals Inc (9IP1.BE)

Should You Retain Your Conviction in Rocket Pharmaceuticals (RCKT)?

EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia

Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia

Why Is Rocket Pharmaceuticals (RCKT) Down 13.6% Since Last Earnings Report?

Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team

Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

15 Best Strong Buy Stocks To Invest In

Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

7 Speculative Stocks to Double Your Money THIS Year

Should You Maintain Your Conviction in Rocket Pharmaceuticals (RCKT)?

Rocket Pharmaceuticals, Inc.'s (NASDAQ:RCKT) Shift From Loss To Profit

Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference

11 Most Promising Biotech Stocks to Buy According to Analysts

Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors

Billionaire Lee Ainslie’s Top 10 Stock Picks

Rocket (RCKT) Surges 40% in 3 Months on Regulatory Updates

Wall Street Analysts See a 167.09% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High?

Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals Stock Sees Improved Price Strength

Performance Overview